[ad_1]
This week's news from the scientific sessions of the American Heart Association Scientific Sessions have been the most widely read stories in cardiology. The meeting coverage highlighted ways to improve cardiovascular disease prevention, CV care and issues affecting patients and providers. The new cholesterol guidelines focusing on new medicines and a more personalized risk calculation were also presented at the meeting.
The presentations included several clinical trials. The results of these tests demonstrated that icosapent ethyl reduces the number of ischemic events in high-risk patients, dapagliflozin reduces hospitalization for heart failure in patients with type 2 diabetes and that vitamin D and omega-3 do not reduce major cardiovascular events and cancer.
Prevention at the center of concerns American Heart Association Scientific sessions
The American Heart Association scientific sessions, which will be held November 10-12 in Chicago, will include the publication of two major guidelines on cholesterol and physical activity, the presentation of important scientific data on the prevention of CVD, the use of technology to improve cardiovascular care and an overview of the issues affecting patients and providers. Read more.
Cholesterol guidelines updated with new drugs, more personalized risk calculation
CHICAGO – The new cholesterol guidelines from the American Heart Association, the American College of Cardiology and 10 other companies recommend a progressive approach, including statin, ezetimibe and PCSK9 inhibitors in patients who have previously presented CVD at very high risk. Read more.
REDUCE IT: Icosapent Ethyl Reduces Ischemic Events in High-Risk Patients
CHICAGO – In patients with elevated triglyceride levels and high CV risk despite statin therapy, icosapent ethyl was superior to placebo in reducing the risk of ischemic events, according to the results of the study. early test REDUCE-IT. Read more.
DECLARE-TIMI 58: Reduced Dapagliflozin cardiac arrest hospitalization in type 2 diabetes
CHICAGO – The DECLARE-TIMI 58 trial of dapagliflozin in patients with type 2 diabetes who were at or at high risk for atherosclerotic CVD adds to the growing body of evidence demonstrating the positive effects of SGLT2 inhibitors on cardiovascular risk. Read more.
VITAL: Vitamin D and Omega-3 fail to reduce major cardiovascular events and cancer
CHICAGO – In the large-scale VITAL trial, neither omega-3 nor vitamin D supplements for primary prevention reduced major cardiovascular events or the development of invasive cancers compared to placebo over the five years of follow-up. Read more.
[ad_2]
Source link
